Back

Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: 18-Month Real-World Experience in 11,991 Patients

2025-11-21 gastroenterology Title + abstract only
View on medRxiv
Show abstract

BackgroundBarretts esophagus (BE), characterized by specialized intestinal metaplasia (SIM), is the precursor to esophageal adenocarcinoma (EAC). Despite published BE screening guidelines for at-risk individuals, uptake of endoscopic screening remains low. We present 18 months of real-world data on non-endoscopic BE screening using EsoGuard(R) (EG), the first commercially available U.S. molecular biomarker test for this purpose, performed on esophageal cell samples collected with the swallowable...

Predicted journal destinations